Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis

• Main Authors: Maria N Zakharova, Anna A Abramova
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2022-01-01
• Series: Neural Regeneration Research
• Subjects: amyotrophic lateral sclerosis; biomarkers of progression; classification; diagnostic biomarkers; disease heterogeneity; electrodiagnostic medicine; electromyography; motor neuron disease; neuroimaging
• Online Access: http://www.nrronline.org/article.asp?issn=1673-5374;year=2022;volume=17;issue=1;spage=65;epage=73;aulast=Zakharova

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive muscle wasting, breathing and swallowing difficulties resulting in patient’s death in two to five years after disease onset. In amyotrophic lateral sclerosis, both upper and lower motor neurons of the corticospinal tracts are involved in the process of neurodegeneration, accounting for great clinical heterogeneity of the disease. Clinical phenotype has great impact on the pattern and rate of amyotrophic lateral sclerosis progression and overall survival prognosis. Creating more homogenous patient groups in order to study the effects of drug agents on specific manifestations of the disease is a challenging issue in amyotrophic lateral sclerosis clinical trials. Since amyotrophic lateral sclerosis has low incidence rates, conduction of multicenter trials requires certain standardized approaches to disease diagnosis and staging. This review focuses on the current approaches in amyotrophic lateral sclerosis classification and staging system based on clinical examination and additional instrumental methods, highlighting the role of upper and lower motor neuron involvement in different phenotypes of the disease. We demonstrate that both clinical and instrumental findings can be useful in evaluating severity of upper motor neuron and lower motor neuron involvement and predicting the following course of the disease. Addressing disease heterogeneity in amyotrophic lateral sclerosis clinical trials could lead to study designs that will assess drug efficacy in specific patient groups, based on the disease pathophysiology and spatiotemporal pattern. Although clinical evaluation can be a sufficient screening method for dividing amyotrophic lateral sclerosis patients into clinical subgroups, we provide proof that instrumental studies could provide valuable insights in the disease pathology.